ABBOTT ENROLLS FIRST PATIENT IN NEW CLINICAL TRIAL OF XIENCE V DRUG ELUTING STENT

Abbott announced Aug. 15 the enrollment of the first patient in its SPIRIT IV clinical trial for the continued evaluation of the safety and efficacy of the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in a more complex patient population. Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=49578&nfid=rssfeeds)